Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial

Autor: Galderisi S., Mucci A., Bitter I., Libiger J., Bucci P., Wolfgang Fleischhacker W., Kahn R. S., Fleischhacker W. W., Boter H., Keet I. P. M., Brugman C., Davidson M., Dollfus S., Gaebel W., Gheorghe M., Gonen I., Grobbee D. E., Hranov L. G., Hummer M., Lindefors N., Lopez-Ibor J. J., Nijssen K., Peuskens J., Prelipceanu D., Riecher-Rossler A., Rybakowski J. K., Sedvall G., Von Wilmsdorff M.

Publikováno v: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 23(3)

Negative symptoms that do not improve following antipsychotic treatment represent a challenge for development of effective treatments. Few studies have been carried out so far, especially in first-episode schizophrenia patients, to clarify prevalence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84f07af2911be9aa247eaad76576ef4b
https://pubmed.ncbi.nlm.nih.gov/22647933

Reducing the treatment gap for mental disorders: A WPA survey

Autor: Patel, V, Maj, M, Flisher, AJ, De Silva, MJ, Koschorke, M, Prince, M, WPA Zonal, Member Society Representatives, Tempier, R, Riba, M, Sanchez, M, Delgado Campodonico, F, Risco, L, Gask, L, Wahlberg, H, Roca, M, Lecic Tosevski, D, Soghoyan, A, Moussaoui, D, Baddoura, C, Adeyemi, J, Rataemane, S, Jalili, SA, Mohandas, E, Shinfuku, N, Freidin, J, Stagnaro, JC, Puig, IJ, Kirkby, K, Musalek, M, Ismayilov, N, Rabbani, G, Harvey, S, Sabbe, B, Noya Tapia, N, Burgic Radmanovic, M, Hetem, LA, Vasconcellos, F, Maass , J, Miranda, C, Papaneophytou, N, Raboch, J, Fink Jensen, A, Okasha, A, Korkeila, J, Guelfi, JD, Schneider, F, Ohene, S, Christodoulou, G, Soldatos, CR, See King, EQ, Mendoza, M, Kallivayalil, RA, Gudarzi, SS, Lafta, MR, Bassi, M, CLERICI, MASSIMO, Gibson, R, Kojima, T, Nurmagambetova, S, Cho, SC, Kadyrova, T, Mikati, N, Bajraktarov, S, Hoe Yen, T, Ayushjav, B, Stevovic, LI, Sequeira Molina, JS, Gureje, O, Johannessen, JO, Chaudhry, HR, Al Ashhab, B, Araszkiewicz, A, Prelipceanu, D, Krasnov, V, Bogdanov, A, Jasovic Gasic, M, Vavrusova, L, Pregelj, P, Liria , AF, Abdelrahman, A, Udomratn, P, Ulas, H, Gokalp, P, Kigozi, FN, Richardson, G.

The treatment gap for people with mental disorders exceeds 50% in all countries of the world, approaching astonishingly high rates of 90% in the least resourced countries. We report the findings of the first systematic survey of leaders of psychiatry

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::320a5ce8dc023155f204c3f7efe7ec1f
http://hdl.handle.net/10281/28515

Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study

Autor: Tohen, M., Eduard Vieta, Goodwin, G. M., Sun, B., Amsterdam, J. D., Banov, M., Shekhar, A., Aaronson, S. T., Bardenstein, L., Grecu-Gaboş, I., Tochilov, V., Prelipceanu, D., Oliff, H. S., Kryzhanovskaya, L., Bowden, C.

Publikováno v: Scopus-Elsevier

OBJECTIVE: To evaluate the efficacy and safety of olanzapine, divalproex, and placebo in a randomized, double-blind trial in mild to moderate mania (DSM-IV-TR criteria). METHOD: The study was conducted from October 2004 to December 2006. A total of 5

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b9301911765845124fb6ee1a5865183f
http://ora.ox.ac.uk/objects/uuid:224a2068-fec8-41f0-a953-0767ba8ae439

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.